KR101842978B1 - 에즈린-유래 펩티드 및 이의 약제학적 조성물 - Google Patents

에즈린-유래 펩티드 및 이의 약제학적 조성물 Download PDF

Info

Publication number
KR101842978B1
KR101842978B1 KR1020160068187A KR20160068187A KR101842978B1 KR 101842978 B1 KR101842978 B1 KR 101842978B1 KR 1020160068187 A KR1020160068187 A KR 1020160068187A KR 20160068187 A KR20160068187 A KR 20160068187A KR 101842978 B1 KR101842978 B1 KR 101842978B1
Authority
KR
South Korea
Prior art keywords
peptide
peptides
seq
treatment
hep
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020160068187A
Other languages
English (en)
Korean (ko)
Other versions
KR20160141673A (ko
Inventor
홈즈 루퍼트
아타울라카노브 라브스한
아타울라카노브 루스탐
사야디안 카치크
Original Assignee
니어메딕 인터네셔널 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니어메딕 인터네셔널 리미티드 filed Critical 니어메딕 인터네셔널 리미티드
Publication of KR20160141673A publication Critical patent/KR20160141673A/ko
Application granted granted Critical
Publication of KR101842978B1 publication Critical patent/KR101842978B1/ko
Assigned to 뉴얼알앤디 엘티디 reassignment 뉴얼알앤디 엘티디 권리의 전부이전등록 Assignors: 니어메딕 인터네셔널 리미티드
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4735—Villin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
KR1020160068187A 2015-06-01 2016-06-01 에즈린-유래 펩티드 및 이의 약제학적 조성물 Expired - Fee Related KR101842978B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2015120667 2015-06-01
RU2015120667 2015-06-01

Publications (2)

Publication Number Publication Date
KR20160141673A KR20160141673A (ko) 2016-12-09
KR101842978B1 true KR101842978B1 (ko) 2018-03-29

Family

ID=56117690

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020160068187A Expired - Fee Related KR101842978B1 (ko) 2015-06-01 2016-06-01 에즈린-유래 펩티드 및 이의 약제학적 조성물

Country Status (26)

Country Link
US (1) US9682140B2 (https=)
EP (1) EP3191504B1 (https=)
JP (1) JP6721419B2 (https=)
KR (1) KR101842978B1 (https=)
CN (1) CN106188267B (https=)
AU (1) AU2016203656B2 (https=)
CA (1) CA2931875C (https=)
CY (1) CY1120501T1 (https=)
DK (1) DK3191504T3 (https=)
ES (1) ES2660894T3 (https=)
GB (1) GB2546439B (https=)
HR (1) HRP20180560T1 (https=)
HU (1) HUE038737T2 (https=)
LT (1) LT3191504T (https=)
MA (1) MA39421A (https=)
MD (1) MD3191504T2 (https=)
ME (1) ME03033B (https=)
MX (1) MX377333B (https=)
PL (1) PL3191504T3 (https=)
PT (1) PT3191504T (https=)
RS (1) RS57067B1 (https=)
SG (1) SG10201604401UA (https=)
SI (1) SI3191504T1 (https=)
SM (1) SMT201800190T1 (https=)
WO (1) WO2016193285A1 (https=)
ZA (1) ZA201603723B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11174288B2 (en) 2016-12-06 2021-11-16 Northeastern University Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria
CN106596977B (zh) * 2017-02-08 2018-06-08 南京医科大学第一附属医院 ezrin在制备哮喘诊断试剂中的应用
WO2021198346A2 (en) 2020-04-01 2021-10-07 Dr. Nesselhut Besitzgesellschaft Mbh Ezrin peptide 1 for use in a method of treating covid-19
CA3173136A1 (en) * 2020-04-01 2021-10-07 Thomas Nesselhut Ezrin peptide 1 for use in a method of treating covid-19
EP4313108A1 (en) 2021-03-31 2024-02-07 Pantapharm AG Ezrin peptide 1 for use in a method of treating post covid-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2290293A (en) 1994-06-08 1995-12-20 Rupert Donald Holms Preparation which inhibits the autoimmune response in HIV, or SLE, patients
GB2354241A (en) * 1999-09-17 2001-03-21 Rupert Donald Holms Regulatory/unfolding peptides of ezrin
GB0301879D0 (en) 2003-01-27 2003-02-26 Regent Res Llp HCV combination therapy
WO2007060440A2 (en) 2005-11-23 2007-05-31 Regent Research L.L.P. The use of peptides in anti-ulcer therapy

Also Published As

Publication number Publication date
SG10201604401UA (en) 2017-01-27
KR20160141673A (ko) 2016-12-09
GB2546439B (en) 2020-08-26
CA2931875A1 (en) 2016-12-01
HRP20180560T1 (hr) 2018-05-04
CN106188267A (zh) 2016-12-07
DK3191504T3 (en) 2018-04-30
CN106188267B (zh) 2020-11-06
ME03033B (me) 2018-10-20
SI3191504T1 (en) 2018-04-30
PL3191504T3 (pl) 2018-08-31
EP3191504B1 (en) 2018-01-17
LT3191504T (lt) 2018-04-10
WO2016193285A1 (en) 2016-12-08
BR102016012501A2 (pt) 2020-04-28
NZ720748A (en) 2023-09-29
ES2660894T3 (es) 2018-03-26
JP2017025055A (ja) 2017-02-02
JP6721419B2 (ja) 2020-07-15
RS57067B1 (sr) 2018-06-29
GB2546439A (en) 2017-07-19
AU2016203656A1 (en) 2016-12-15
MD3191504T2 (ro) 2018-04-30
SMT201800190T1 (it) 2018-05-02
US20160346383A1 (en) 2016-12-01
PT3191504T (pt) 2018-04-16
ZA201603723B (en) 2019-03-27
HUE038737T2 (hu) 2018-11-28
MX2016007122A (es) 2017-01-25
AU2016203656B2 (en) 2020-02-06
MA39421A (fr) 2017-07-19
EP3191504A1 (en) 2017-07-19
CA2931875C (en) 2022-06-21
GB201705990D0 (en) 2017-05-31
US9682140B2 (en) 2017-06-20
CY1120501T1 (el) 2019-07-10
MX377333B (es) 2025-03-06

Similar Documents

Publication Publication Date Title
KR101842978B1 (ko) 에즈린-유래 펩티드 및 이의 약제학적 조성물
KR102489519B1 (ko) 급성 호흡기 바이러스 감염 치료용 항바이러스 면역 억제제
NO326298B1 (no) Anvendelse av R'-Glu-Trp-R'' dipeptider i fremstilling av medikamenter
KR20150014955A (ko) 펩티드의 히드로클로라이드 염 및 다른 펩티드와 조합한 그의 면역요법을 위한 용도
CN103200955A (zh) 包含肽和病毒神经氨酸酶抑制剂的组合物
JP6464507B2 (ja) 抗ウイルス剤、および抗菌剤
IE65533B1 (en) Hemoregulatory peptides
RU2694906C2 (ru) Пептиды производные эзрина и фармацевтические композиции на их основе
US20250059232A1 (en) Pentapeptide and use thereof
CN101671390A (zh) 人干扰素α衍生物及其聚乙二醇化修饰物的制备和用途
NZ720748B2 (en) Ezrin-derived peptides and pharmaceutical compositions thereof
BR102016012501B1 (pt) Peptídeo, composição farmacêutica, uso do peptídeo e uso da composição farmacêutica
KR102544102B1 (ko) 상처 치료 및 항염증 활성을 가지는 펩타이드 및 이의 용도
RU2721282C2 (ru) Способ лечения рассеянного склероза (варианты)
US7750114B2 (en) Peptides having a high cysteine content
JPH03170498A (ja) ペプチドおよびこのペプチドを含有する薬剤
KR20160091304A (ko) 인터페론 접합체를 포함하는 조성물 및 이의 제조방법
KR20170055463A (ko) 인터페론 접합체를 포함하는 조성물 및 이의 제조방법
CN1831004A (zh) 棕点湍蛙抗病毒多肽及其在制药中的应用
HK1070835A1 (en) Pharmaceutical compositions for the treatment of sars
HK1070835B (en) Pharmaceutical compositions for the treatment of sars
KR20160022502A (ko) 인터페론 접합체를 포함하는 복합체 및 이의 제조방법

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250323

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-OTH-PC1903 (AS PROVIDED BY THE NATIONAL OFFICE); TERMINATION CATEGORY : DEFAULT_OF_REGISTRATION_FEE

Effective date: 20250323

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250323